Skip to main content

Advertisement

SpringerLink
Log in

Ophthalmic Delivery of Brinzolamide by Liquid Crystalline Nanoparticles: In Vitro and In Vivo Evaluation

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Brinzolamide (BLZ) is a drug used to treat glaucoma; however, its use is restricted due to some unwanted adverse events. The goal of this study was to develop BLZ-loaded liquid crystalline nanoparticles (BLZ LCNPs) and to figure out the possibility of LCNPs as a new therapeutic system for glaucoma. BLZ LCNPs were produced by a modified emulsification method and their physicochemical aspects were estimated. In vitro release study revealed BLZ LCNPs displayed to some extent prolonged drug release behavior in contrast to that of BLZ commercial product (Azopt®). The ex vivo apparent permeability coefficient of BLZ LCNP systems demonstrated a 3.47-fold increase compared with that of Azopt®. The pharmacodynamics was checked over by calculating the percentage fall in intraocular pressure and the pharmacodynamic test showed that BLZ LCNPs had better therapeutic potential than Azopt®. Furthermore, the in vivo ophthalmic irritation was evaluated by Draize test. In conclusion, BLZ LCNPs would be a promising delivery system used for the treatment of glaucoma, with advantages such as lower doses but maintaining the effectiveness, better ocular bioavailability, and patient compliance compared with Azopt®.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Quigley H, Broman A. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–7.

    Article  PubMed  CAS  Google Scholar 

  2. Becher B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox: a preliminary report. Am J Ophthalmol. 1954;37:13–5.

    Google Scholar 

  3. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126:400–8.

    Article  PubMed  CAS  Google Scholar 

  4. Michaud J, Friren B. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:235.

    Article  PubMed  CAS  Google Scholar 

  5. March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2000;129:136–43.

    Article  PubMed  CAS  Google Scholar 

  6. Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt®) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol. 2000;44:S163–8.

    Article  PubMed  Google Scholar 

  7. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev. 1995;16:75–93.

    Article  CAS  Google Scholar 

  8. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev. 1995;16:61–73.

    Article  CAS  Google Scholar 

  9. Yamaguchi M, Yasueda S, Isowaki A, Yamamoto M, Kimura M, Inada K, et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm. 2005;301:121–8.

    Article  PubMed  CAS  Google Scholar 

  10. Han S, Shen J, Gan Y, Geng H, Zhang X, Zhu C, et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin. 2010;31:990–8.

    Article  PubMed  CAS  Google Scholar 

  11. Esposito E, Cortesi R, Drechsler M, Paccamiccio L, Mariani P, Contado C, et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm Res. 2005;22:2163–73.

    Article  PubMed  CAS  Google Scholar 

  12. Hirlekar R, Jain S, Patel M, Garse H, Kadam V. Hexosomes: a novel drug delivery system. Curr Drug Deliv. 2010;7:28.

    Article  PubMed  CAS  Google Scholar 

  13. Lopes LB, Ferreira DA, de Paula D, Garcia MTJ, Thomazini JA, Fantini MCA, et al. Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A. Pharm Res. 2006;23:1332–42.

    Article  PubMed  CAS  Google Scholar 

  14. Swarnakar NK, Jain V, Dubey V, Mishra D, Jain N. Enhanced oromucosal delivery of progesterone via hexosomes. Pharm Res. 2007;24:2223–30.

    Article  PubMed  CAS  Google Scholar 

  15. Boyd BJ, Whittaker DV, Khoo SM, Davey G. Hexosomes formed from glycerate surfactants—formulation as a colloidal carrier for irinotecan. Int J Pharm. 2006;318:154–62.

    Article  PubMed  CAS  Google Scholar 

  16. Amar-Yuli I, Wachtel E, Shoshan EB, Danino D, Aserin A, Garti N. Hexosome and hexagonal phases mediated by hydration and polymeric stabilizer. Langmuir. 2007;23:3637–45.

    Article  PubMed  CAS  Google Scholar 

  17. Lee J, Kellaway IW. Buccal permeation of [D-Ala2, D-Leu5] enkephalin from liquid crystalline phases of glyceryl monooleate. Int J Pharm. 2000;195:35–8.

    Article  PubMed  CAS  Google Scholar 

  18. Lee J, Kellaway IW. Combined effect of oleic acid and polyethylene glycol 200 on buccal permeation of [D-Ala2, D-Leu5] enkephalin from a cubic phase of glyceryl monooleate. Int J Pharm. 2000;204:137–44.

    Article  PubMed  CAS  Google Scholar 

  19. Gan L, Han S, Shen J, Zhu J, Zhu C, Zhang X, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm. 2010;396:179–87.

    Article  PubMed  CAS  Google Scholar 

  20. Hägerström H, Paulsson M, Edsman K. Evaluation of mucoadhesion for two polyelectrolyte gels in simulated physiological conditions using a rheological method. Eur J Pharm Sci. 2000;9:301–9.

    Article  PubMed  Google Scholar 

  21. Ye J, Wang Q, Zhou X, Zhang N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm. 2008;352:273–9.

    Article  PubMed  CAS  Google Scholar 

  22. Huo D, Deng S, Li L, Ji J. Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting. Int J Pharm. 2005;289:63–7.

    Article  PubMed  CAS  Google Scholar 

  23. Suhonen P, Jarvinen T, Peura P, Urtti A. Permeability of pilocarpic acid diesters across albino rabbit cornea in vitro. Int J Pharm. 1991;74:221–8.

    Article  CAS  Google Scholar 

  24. Liu J, Fu S, Wei N, Hou Y, Zhang X, Cui H. The effects of combined menthol and borneol on fluconazole permeation through the cornea ex vivo. Eur J Pharmacol. 2012;688:1–5.

    Article  PubMed  CAS  Google Scholar 

  25. Ammar HO, Salama H, Ghorab M, Mahmoud A. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009;10:808–19.

    Article  PubMed  CAS  Google Scholar 

  26. Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377–90.

    CAS  Google Scholar 

  27. Das S, Suresh PK, Desmukh R. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine. 2010;6:318–23.

    Article  PubMed  CAS  Google Scholar 

  28. Palma SD, Tartara LI, Quinteros D, Allemandi DA, Longhi MR, Granero GE. An efficient ternary complex of acetazolamide with HP-ss-CD and TEA for topical ocular administration. J Control Release. 2009;138:24–31.

    Article  PubMed  CAS  Google Scholar 

  29. Seddon JM. Structure of the inverted hexagonal (H II) phase, and non-lamellar phase transitions of lipids. Biochim Biophys Acta. 1990;1031:1–69.

    Article  PubMed  CAS  Google Scholar 

  30. Monduzzi M, Ljusberg-Wahren H, Larsson K. A 13C NMR study of aqueous dispersions of reversed lipid phases. Langmuir. 2000;16:7355–8.

    Article  CAS  Google Scholar 

  31. Libster D, Ishai PB, Aserin A, Shoham G, Garti N. Molecular interactions in reverse hexagonal mesophase in the presence of Cyclosporin A. Int J Pharm. 2009;367(1):115–26.

    Article  PubMed  CAS  Google Scholar 

  32. Barauskas J, Cervin C, Jankunec M, Špandyreva M, Ribokaitė K, Tiberg F, et al. Interactions of lipid-based liquid crystalline nanoparticles with model and cell membranes. Int J Pharm. 2010;391:284–91.

    Article  PubMed  CAS  Google Scholar 

  33. Taskovich LT. Skin permeation enhancer compositions using glycerol monooleate. Google Patents. 1989.

  34. Saettone MF, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four β-blockers, and in vitro/in vivo toxic activity. Int J Pharm. 1996;142:103–13.

    Article  Google Scholar 

  35. Akman A, Cetinkaya A, Akova Y, Ertan A. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. Eye. 2004;19:145–51.

    Article  Google Scholar 

  36. Boyd BJ, Whittaker DV, Khoo SM, Davey G. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Int J Pharm. 2006;309:218–26.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are grateful for the financial support from the National Natural Science Foundation of China (81273457); National Natural Science Foundation of Jiangsu Province (BK2012445, BK2012843); and Science and Technology Development Foundation of Nanjing Medical University (2011NJMU271).

Conflict of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Author information

Authors and Affiliations

  1. School of Pharmacy, Nanjing Medical University, Lane 818, East Tianyuan Road, Nanjing, Jiangsu, 211166, People’s Republic of China

    Weijun Wu, Jing Li, Lin Wu, Baoyan Wang, Zhongyuan Wang, Qunwei Xu & Hongliang Xin

Authors
  1. Weijun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Baoyan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhongyuan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qunwei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hongliang Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Qunwei Xu or Hongliang Xin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, W., Li, J., Wu, L. et al. Ophthalmic Delivery of Brinzolamide by Liquid Crystalline Nanoparticles: In Vitro and In Vivo Evaluation. AAPS PharmSciTech 14, 1063–1071 (2013). https://doi.org/10.1208/s12249-013-9997-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-013-9997-2

Key words

Search

Navigation